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Pharmaceutical Statistics. 2018;17:593–606.This paper provides an overview of “Improving Design, Evaluation and
Analysis of early drug development Studies” (IDEAS), a European Commis-
sion–funded network bringing together leading academic institutions and
small‐ to large‐sized pharmaceutical companies to train a cohort of graduate‐
level medical statisticians. The network is composed of a diverse mix of public
and private sector partners spread across Europe, which will host 14 early‐stage
researchers for 36 months. IDEAS training activities are composed of a well‐
rounded mixture of specialist methodological components and generic trans-
ferable skills. Particular attention is paid to fostering collaborations between
researchers and supervisors, which span academia and the private sector.
Within this paper, we review existing medical statistics programmes (MSc
and PhD) and highlight the training they provide on skills relevant to drug
development. Motivated by this review and our experiences with the IDEAS
project, we propose a concept for a joint, harmonised European PhD pro-
gramme to train statisticians in quantitative methods for drug development.
KEYWORDS
development of early‐stage researchers, drug development, PhD curriculum, regulatory statistics,
university‐industry partnership- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
reative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
ished by John Wiley & Sons Ltd.
wileyonlinelibrary.com/journal/pst 593
594 JAKI ET AL.1 | INTRODUCTION
Drug development is a long and costly process. This, pairedwith the high levels of attrition seen even at late stages of the process,
has increased the emphasis being placed on quantitative decision‐making during the biopharmaceutical development process.
More quantitative assessment of risk is now performed when moving from early‐ to late‐stage clinical trials, for example.
To avoid lengthy and expensive confirmatory studies, the use of efficient methods for the design and analysis of early‐phase
clinical studies is essential. The challenges faced by statisticians working in this field1-3 range from model specification,4 small
sample sizes,5,6 and complex in silico simulations, to how relevant information can be translated and used. In recent years,
demand for quantitative skills fromboth academia and industry has surged due to greater emphasis being placed on quantitative
benefit‐risk assessment, dose‐finding, extrapolation, and the use of related data. For example, there are now several initiatives
allowing access to individual patient data,7 which have resulted in the wider uptake of Bayesian methods as this facilitates
the use of informative priors and innovative clinical trial designs8,9 to directly incorporate available information in decision‐
making. One of the challenges with this more quantitative approach is that expertise in these methods is limited; this is in part
due to them being quite specialised so that they are not routinely covered in standard educational programmes. Another impor-
tant facet of a statistician's work is that they collaborate with multidisciplinary teams, another aspect not captured by current
training programmes. Although it is explicitly stated in ICH guidelines E610 and E911 that a statistician must be involved in the
conduct of a clinical trial and the multiple demands on a statistician in the pharmaceutical industry have been discussed in
Chuang‐Stein et al,12 there is no unique definition of what core training a statistician should receive. Despite the lack of unique
definition, a survey by the European Federation of Statistician in the Pharmaceutical Industry in 1999 already shows that a
notable portion of statisticians (10%‐40%) in the European industry has a PhD.13 A follow‐on survey undertaken among IDEAS
partners shows that this has risen to at least 30% by 2018 and in some companies and regions is well over 50%.
In this paper, we will describe the approach taken by the IDEAS network on “Improving Design, Evaluation and Anal-
ysis of early drug development Studies” (www.ideas‐itn.eu) funded by the European Commission (EC) under the Marie
Sklodowska‐Curie Actions to overcome this challenge to educate world‐class PhD‐level researchers. We argue that an
expanded pan‐European curriculum is the logical next step towards ensuring a continued supply of well‐educated statis-
ticians who are prepared for careers in the pharmaceutical industry, regulatory agencies, or public sector medical research
organisations. In Section 2, we explore the training typically offered by relevant MSc programmes (eg, MSc in [Medical]
Statistics andMSc in Biometry). We then highlight the specific requirements of current European PhD schemes in Section
3 and subsequently summarise other relevant formal accreditations available from learned societies (Section 4). In Section
5, we describe the IDEAS approach, focusing on the added value of the programme before we state our case for the devel-
opment of a harmonised curriculum and critically evaluate the impact and risk of such a venture (Section 6).2 | EXISTING MSc PROGRAMMES
The natural start for someone aspiring to work as a statistician in drug development in Europe is to undertake an MSc in
(Medical) Statistics. The typical training elements of such degree schemes are highlighted in Table 1. Because of space and
language constraints, we limit this illustration to countries IDEAS partners are affiliated with. Typically full‐timeMSc studies
last between 1 and 2 years and comprise a set of compulsory and optional courses that culminate in a master's thesis.
A more detailed overview of the taught courses in the European MSc programmes above and all relevant Msc
programmes in the UK is provided in Supporting Information (Tables S1 and S2). We list the compulsory modules in
full for each programme but only include those optional courses that are particularly relevant to someone seeking to
work with clinical trials. The compulsory modules for a large part focus on the fundamentals of statistics, such as infer-
ence, Bayesian methods, and computational statistics, while optional courses include “Introduction to clinical trials”
and “Methods for analysing genetic data.” There is a lack of more specialised courses. For example, except for Lancaster
University and the University of Dortmund, none of the programmes offer courses on adaptive methods or dose‐finding
—topics highly relevant to drug development and at the forefront of ideas to improve the efficiency of clinical trials. As
pointed out by one reviewer, there is only a limited amount of space in an MSc curriculum available and many compet-
ing topics. Such highly specialist modules at a level suitable for an MSc require lecturers who know the topic well,
which demonstrates that our PhD programme would also address the academic need for experts in certain fields.
It is also notable that none of the programmes explicitly cites training in transferable skills as part of their curriculum.
Although some aspects such as consultancy and presentation skills will likely be covered at most institutions as part of the
offered courses, the distinct lack of explicit training indicates that this is not a highly valued part of the curriculum.
TABLE 1 Key aspects of MSc programmes in Europe on the example of countries affiliated with IDEAS
Country Institution
Duration
and Credits Area of Study
Credits for
Thesis
Compulsory
Modules
Elective
Modules
Austria Universitat Wien 2 y (120 credits) Master's in Statistics 20 90 10
Belgium Hasselt University 2 y (120 credits) Master's in Statistics 24 89 7
Denmark University of
Copenhagen
2 y (120 credits) MSc Statistics 30 30 60
France Université Pierre et
Marie Curie ‐ Paris 6
2 y (120 credits) Msc in Mathematics
and applications
18 36 66
Germany University Dortmund 2 y (120 credits) 30 40 50
Germany Universitat Bremen 2 y (120 credits) MSc Medical Biometry/
Biostatistics
30 82 8
Greece University of Athens 2 y (120 credits) MSc Biostatistics 30 62 28
Ireland University College Dublin 1 y (90 credits) MSc Statistics 25 12.5 52.5
Italy University of Bologna 2 y (120 credits) MSc Statistical
Sciences
30 80 10
Poland Wroclaw University 2 y (120 credits) Master's in Mathematical
Statistics
18 49 53
Spain Universidade de Santiago
de Compostela
18 mo (90 credits) Master's in Statistical
Techniques
10 30 50
Switzerland University of Geneva 18 mo (90 credits) MSc Statistics 30 33 27
United Kingdom Lancaster University 12 mo (180 credits) MSc in Statistics 60 70 50
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length but can be substantially longer at non‐UK institutions—in France, it usually lasts around 6 mo), focus is on one
specific research question while methods and results are recorded in a report of 30 to 50 pages in length. Topics include
theoretical/simulation–based as well as data‐based investigations. Pharmaceutical companies can either contribute
topics and cosupervise students or occasionally host students subject to approval by the university. Clearly, opportuni-
ties exist for projects with industry, but in our experience, these are the exception rather than the norm.
As a result of the content and structure of these programmes, graduates can be expected to have a solid grounding in
the foundations of statistics. Beyond that, however, they will have had limited training in the additional skills required
for drug development.3 | FURTHER TRAINING THROUGH A PhD
One path often taken by junior researchers on their way to employment in drug development (eg, in industry, in a reg-
ulatory agency, in a contract research organisation [CRO], or in an academic clinical trials unit) is to follow their
master's degree with a PhD. Many different PhD programmes exist, but again, the broad structure of these degrees is
quite similar. The focus is on pursuing a research question. Although the question is often developed in conjunction
with their supervisors, the student's work should be undertaken independently with some guidance by the supervisor.
Despite some dedicated initiatives from public sector funders through cofunded studentships (eg, MRC CASE student-
ships) where students are hosted at academic institutions, or arrangements where the main basis of work can be within
an industry partner (eg, Baekeland mandates), joint PhD projects with industry remain, however, the exception. The
MRC CASE studentships, for example, only make up around 15% of MRC‐funded PhD places.
While most doctoral programmes in Statistics in Europe have the expectation that the student should also undertake
further training beyond the research project, the extent to which this training is compulsory is often limited.
Table 2 summarises the formal requirements and further training expectations for universities that are part of the
IDEAS network. While we do not claim that this is an exhaustive list of relevant PhD schemes, it does serve as a refer-
ence of what is considered typical for a PhD in Statistics (or related field) within Europe.
TABLE 2 Summary of PhD requirements of universities enrolling students on the IDEAS project
Institution Further Training Completion Requirement
Lancaster University Expectation of 10 training days per year,
which includes courses, seminars, workshops,
and conferences
– Min 3 y;
– PhD thesis containing significant novel research.
Medical University
of Vienna
Several specific courses ranging from biomedical
propaedeutics to journal clubs worth 34 ECTS
credits
– Min 3 y (total 180 ECTS);
– PhD thesis containing significant novel research
(146 ECTS);
– Completion of specific set of courses worth 34
ECTS credits.
Politecnico Di Torino Twenty‐four ECTS worth of courses and workshops
that can be freely chosen. At least 12 ECTS must
come from lectures.
– Min 3 y;
– PhD thesis containing significant novel research;
– Completion of 24 ECTS credits worth of courses
and workshops and attendance to seminars;
– PhD awarded as “PD. in Mathematical
Engineering”;
– Short presentation of work when passing from
years 1 to 2 and from years 2 to 3.
Universität Bremen Expectation to undertake training in scientific
writing, presentation skills, ….
– Min 3 y;
– PhD thesis containing significant novel research.
University Paris Saclay Thirty credits required over duration of studies.
One credit is equivalent to 1 training day.
– Min 3 years;
– PhD thesis containing significant novel
research;
– Completion of 30 training credits;
– Two publications as first author.
Hasselt University A set of courses (approximately 50 h in total) is
to be attended.
– Min 4 y;
– PhD thesis containing significant novel research.
Technische Universität
Dortmund
Further optional training available, via either the
statistics courses in the master program or specific
courses on different nonstatistics topics, attendance
of external trainings, workshops, and conferences.
– PhD thesis containing significant novel research;
– Twenty ECTS credits worth of courses to be chosen
from specific courses in the master's programme
– Attendance of 20 departmental seminars
– Two presentations in departmental PhD student
seminar (at the beginning and the end of the
PhD time)
596 JAKI ET AL.From this small snapshot, we find that programmes at least have an expectation of some additional training beyond
the main project of the PhD, with a substantial number requiring at least some formal training. Some institutions offer
specific courses for PhD students, while others leave it up to the student/supervisor to decide what training is most
important and appropriate. It is, however, notable that in all cases, this additional training only forms a small part
(between 5% and 19%) of the degree scheme. It is also noteworthy that, with few exceptions, only subject matter training
is deemed important; training on generic or transferable skills is often not explicitly required.
With this background, a new PhD graduate will be highly knowledgeable about their specific area of research but
will often lack a broader awareness of the drug development process beyond the basics taught during their master's pro-
gramme. Some experience with industry is possible for students who have been fortunate enough to work on a joint
project with industry or have had the opportunity to undertake an internship at a company.4 | PROFESSIONAL QUALIFICATIONS FROM LEARNED STATISTICAL SOCIETIES
Although the involvement of a qualified statistician in drug development is an explicit requirement of ICH E6 and
E9,10,11 there is no unique definition of which education or what certificates from learned societies are sufficient. Some
proposals have been published14,15 and some formal certifications to qualify statisticians exist (Table 3), but consensus
appears to be lacking. General certifications are, for example, available from the Royal Statistical Society and the Amer-
ican Statistical Association. However, only the German Society for Medical Computer Science, Biometry, and
TABLE 3 Professional certifications for statistician from professional societies
Organisation (Certificate) Requirements Comments
German Society for Medical
Computer Science, Biometry
and Epidemiology (GMDS)
together with the German
Region of the International
Biometric Society (IBS‐DR)
– A German university degree in medicine;
statistics; or natural, social, or health
sciences (at least to master's level) or a
Master of Public Health or Epidemiology.
– At least 5 y of experience in a relevant field.
– A theoretical training that complements
the input studying the complementary
areas of expertise.
Three types of certification, namely,
“Medical Computer Science,”
“Biometrics in Medicine,” and
“Epidemiology” depending
on the area of work.
Royal Statistical Society (RSS)
Graduate Statistician
– A UK honours degree (class I or II) or
equivalent overseas degree in statistics or
related field.
– Requires revalidation.
Nothing specific to medical statistics
(or drug development)
RSS‐chartered statistician – As above.
– Plus at least 5 y approved professional
training and experience
Nothing specific to medical statistics
(or drug development)
American Statistical
Association (ASA)
graduate statistician (gstat)
– Advanced degree in statistics or a related
quantitative field.
Nothing specific to medical statistics
(or drug development)
American Statistical
Association (ASA)
Accredited professional
statistician (pstat)
– Advanced degree in statistics or a related
quantitative field
– At least 5 y of documented experience in
the employment of appropriate statistical
concepts and techniques
– Required revalidation
Nothing specific to medical statistics
(or drug development)
Statistical Society of Australia
Accredited statistician (AStat)
– A degree with a statistics component
equivalent to that of second‐ or third‐
level statistics subjects or mathematics
majors in Australian universities, plus
6 y practical experience in applying
statistics; or a first‐ or second‐class
honours degree or equivalent in statistics
or in a subject containing substantial
coverage of statistical methods or theory,
plus 4 y practical experience in applying
statistics.
Nothing specific to medical statistics
(or drug development)
Statistical Society of Australia
Graduate statistician (GStat)
– Fulfil the same degree requirement as
for AStat, but completion date less than
8 y ago.
Nothing specific to medical statistics
(or drug development)
Statistical Society of Canada
Associate statistician (AStat)
– Completion of a course of study showing
ability and aptitude in statistics (eg, an
undergraduate degree in Statistics), or,
in exceptional instances, has otherwise
demonstrated an advanced understanding
of statistical theory and its application.
Nothing specific to medical statistics
(or drug development)
Statistical Society of Canada
Professional statistician (PStat)
– As for AStat above
– A minimum of 6 y of professional
experience in the application of statistics
Nothing specific to medical statistics
(or drug development)
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for Statisticians in Medicine.
All accreditations build upon a relevant university degree and have additional requirements with respect to the
extent of practical experience. Additionally, further continued professional development is typically required, although
there is no explicit requirement that this should incorporate elements of transferable skills training.
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In previous sections, we have provided an overview of the conventional training paths available to statisticians and
highlighted what we see as deficiencies in the training opportunities available to those interested in a career in drug
development. These shortcomings are what motivated us to create the IDEAS network.
The network is composed of 8 partners (5 industrial and 3 academic) from 7 European countries (Austria, Belgium,
France, Germany, Italy, Switzerland, and United Kingdom) that host one or more early‐stage researchers (ESRs) and is
supplemented by 8 associated partners (5 industry and 2 academic) that contribute to the training activities of the net-
work. The network is funded by the EC under the Marie Sklodowska‐Curie Actions. The funding covers salary of the
ESRs and training costs (including costs of secondments) as well as management costs.
The primary objective of the network is train ESRs so that they are well equipped to work in drug development and
have a good grasp of methods for studies in the early stages of drug development. Prior to joining, the 14 network ESRs
have, with one exception, completed a master's degree in Statistics or related field (one student started with a BSc and
had completed the first year of a 2‐year master's). The funding application to the EC states specifically that the network
seeks to
a. train ESRs in state‐of‐the‐art methods for designing, evaluating, and analysing early phase studies;
b. develop novel methodology for early‐phase studies through individually supervised, collaborative, research projects;
c. provide an international, collaborative environment, in which the academic research experience is paired with the
challenges of undertaking drug development within the private sector; and
d. raise awareness about cutting‐edge methods for designing and analysing early‐phase studies among statisticians,
trialists, and clinicians alike.
In line with the rest of the manuscript, we will focus on the training of the ESRs (who are completing a PhD in Sta-
tistics or related field as part of their network research) and particularly highlight the novel approach taken. Note that
some elements of what is implemented in IDEAS are also offered as part of other training programmes: The combina-
tion of these elements as well as the focus on early drug development is, however, unique. It should also be noted that
training activities offered by the network are supplementing local requirements (ie, the university‐specific PhD curric-
ulum) rather than superseding them. In some cases, aspects of the IDEAS training are counted as part of the local
requirements (for example, training days for PhD students at Lancaster University). Day‐to‐day management of the net-
work is undertaken by key representatives of each partner institution, along with 2 delegates representing the ESRs.
Furthermore, management is overseen by an external advisory board composed of representatives from academia,
industry, regulatory agencies, and clinical experts.
Traditionally training for medical statisticians is undertaken at academic institutions and at the MSc level both more
theoretical and more practical degrees are offered. Interactions with the private sector or other stakeholders with an
interest in applied problems are, however, far from the norm. The IDEAS network facilitates closer interactions between
academia and the private sector while keeping the needs of clinical colleagues and regulators in sight. To achieve this,
IDEAS ESRs who are based primarily at academic institutions spend secondments in industry and vice versa.
Training activities within the network, detailed below, comprise 4 components:
i. individually supervised research projects;
ii. transnational, cross‐sectorial secondments;
iii. network‐wide training activities; and
iv. individual training activities.5.1 | Individually supervised research projects
The individual research project is, as with all other PhD schemes, the core of the activity of the ESRs. The IDEAS net-
work does, however, take a collaborative approach to this activity so that cross‐sectorial cross‐disciplinary teams super-
vise the researchers. Each researcher is supervised by a primary contact at their host institution, as is typical for PhD
research projects. In addition, a second supervisor also works with the student. The set‐up within IDEAS is such that
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secondary supervisor from within industry and vice versa. This set‐up helps to give the ESRs greater experience of dif-
ferent research environments.
Additionally, supervisor pairings are transnational to allow the ESRs to see beyond national requirements and tra-
ditions. To supplement the methodological aspects of the research project, a clinical advisor is associated with each pro-
ject. The role of this advisor, who is a highly respected researcher in a clinical area relevant to the project and often has
additional experience with regulatory agencies, is to provide high‐level input on the direction and practicability of the
project, provide the researcher with challenging problems from his subject matter field, and support implementation of
the methods when appropriate. For example, in a project on Biosimilars,16 a review on experiences with EU approvals17
was conducted together with the associated clinical advisor.5.2 | Transnational, cross‐sectorial secondments
To further strengthen links between industry and academia and deepen collaborations between supervisory teams, each
ESR will undertake one or more secondments. These transnational, cross‐sectorial secondments are visits to a partner in
the complementary sector of at least 3 months' duration. The primary secondment is typically to the second supervisor's
institution although more than one secondment is common. One of the main objectives of these visits is to expose the
ESR to a different environment. The researchers will thereby gain insights into different host facilities, research, and
training approaches beyond sectorial and national boundaries. The ESR works on problems related to their research
(eg, a student looking a dose‐finding for combination studies might work on a project on combining safety and efficacy
data in a single‐agent study) ideally resulting in joint publications.18-22 In addition, the ESR will also have the opportu-
nity to get involved in the routine activities of a pharmaceutical statistician when seconded to an industry partner and
will be able to contribute to consulting and teaching activities during academic placements. This arrangement also facil-
itates exchanges between the IDEAS partners beyond their specific PhD projects and enables the ESRs to establish a
valuable professional network, which will benefit their future careers.5.3 | Network‐wide training activities
Compulsory network‐wide training sessions feature courses on relevant statistical methods specific to drug development
as well as training on transferable skills. In addition, these events are also used to foster team building and joint
research. Network‐wide activities are structured as
a. four 5‐day summer schools;
b. three e‐learning courses in statistical methodology;
c. one Think Tank meeting; and
d. regular interactive virtual discussion sessions run by and for the ESRs.
The objectives of the summer schools are to provide the ESRs with the relevant statistical skill set alongside more
generic, transferable skills that are essential for any statistician working in medical statistics and in the early phases
of drug development in particular. Additionally, these events include strategies to strengthen network‐wide interactions.
See Table A1 for the complete summer school curriculum.
The e‐learning courses (detailed in Table A2) provide specialist courses in statistical methodology and computing,
allowing the researchers to learn at their own pace, while ensuring personal interaction through online chat sessions
and a discussion forum. The content of some e‐learning courses is subsequently reinforced in practical sessions at the
summer schools.
The Think Tank meeting is held to ensure that the synergies between the different researchers can be used and pro-
vides the ESRs with an opportunity to experience and benefit from a cross‐sectorial collaborative environment.
The final components of training are virtual interactive discussion sessions. These sessions are ESR‐led virtual meet-
ings held every 2 to 3 weeks that allow the researchers to discuss among themselves their projects and the challenges
they are encountering. For many of the sessions, an ESR will present his/her current work, thereby developing their
presentation skills while also providing them with the opportunity to receive constructive feedback on their research.
The virtual sessions are also used to present and discuss individual research projects with the external advisory board
of the IDEAS network, which is composed of one statistician in academia, a statistician working in industry, a member
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students feel they need. For example, a session on “outreach” has been identified in this way.5.4 | Training activities tailored to the individual researcher
The final training component is individual training activities. These activities are established with emphasis on the spe-
cific needs of the individual ESR. The exact training programme is developed and agreed with the supervisory team and
forms the basis of a personal career development plan. The individual training activities may range from specialised
methodology training to career planning sessions to conference attendance. To complement the programme of short
courses available at each partner site, the professional development courses offered at Lancaster University, the Medical
University of Vienna, and the University of Bremen have been made available to all ESRs in the network.6 | ADDED VALUE OF A JOINT CURRICULUM IN QUANTITATIVE
METHODS FOR DRUG DEVELOPMENT
In the previous section, we outlined the approach that the IDEAS network has taken to deliver a state‐of‐the‐art doc-
toral training programme for researchers interested in the statistical issues of the early phases of drug development.
We believe that this initiative should be the first step towards ensuring an adequate pipeline of well‐trained researchers
who can work and lead in the statistics of drug development more broadly. Progressing this idea, we believe that the
next logical step is to establish a dedicated PhD‐level scheme, which can be run across several academic institutions
jointly with the pharmaceutical industry and regulatory authorities and broadening the scope to other phases of drug
development. The pharmaceutical industry and regulatory agencies will contribute by (co)supervising students on pro-
jects of interest to the organisation, teach on the training programme, and provide secondment opportunities. Emerging
topics such as data science and big data to analyse and integrate data from various sources, eg, big data from clinical
trials as well as real‐world evidence (RWE) generated, for example, from registries and health care providers23,24 or
new data sources such as Medical Internet of Things (eg, remote monitoring of patients with electronic devices),25 will
change the way in which evidence is gathered and impact upon the job profile of the clinical statistician. One advantage
of a joint curriculum would be that core training components form an integral (and not optional) part of local doctoral
requirements, as currently the case within IDEAS. Furthermore, a standardisation of the requirements for the thesis and
courses, ie, in terms of European Credit Transfer System (ECTS) points, would also facilitate further mobility of ESRs
across countries. We envisage that students would be able to enrol at any of the participating academic institutions.
Once enrolled, their primary place of research would be at that institution or at a nonacademic partner. However, all
participating ESRs will undertake the same training and processes (in terms of monitoring as well as degree require-
ments) irrespective of their primary site of work. This has the immediate advantage that all graduates from the pro-
gramme would benefit from an established international professional network that spans both academia and
industry. At the same time, this programme can be seen as a specialist certification that graduates have an excellent
working knowledge of the statistics of drug development.
During the preparation of their thesis, a student should be cosupervised by an academic and industry researcher.
The PhD thesis should ideally consist of methodological work, which should be of a standard suitable for publication
in high‐quality peer‐reviewed journals, supplemented by an overarching introduction and discussion. Ideally, at least
one paper should have been accepted by the time of submission, although it is recognised that these timelines are
not within the control of the student. Therefore, the thesis should be assessed by 2 independent experts in the field
and be defended at an oral examination (similar to the viva voce examination in the United Kingdom).
We believe that such a joint curriculum must require students to have spent a minimum of 3 months at a pharma-
ceutical company or regulator and have worked with at least 2 different organisations located in different countries.
Moreover, we believe that it is essential that students are taught the areas detailed in Table 4. These courses, which
we feel are a minimum requirement, will certainly need to be supplemented by training in areas relevant to the
researcher's project (eg, survival analysis for a project related to this topic). The compulsory training should be organised
as training blocks, and some additional courses should be offered online (with assessed components).
Additionally, we are convinced that it is paramount that each student should receive training in the transferable and
generic skills given in Table 5 to thrive in their future roles.
TABLE 4 Formal training for a curriculum in statistics in drug development
Overview of the drug development process
Relevance: Fundamental understanding of drug development
Duration: 2 d (16 h) F2F/4 h online
Topics: General overview on drug development (safety, preclinic, phases I‐IV, …), different study designs (such as parallel vs crossover studies
and superiority vs equivalence), sample size, determination, regulatory aspects (eg, relevant guidelines and clinical trial regulation),
quantitative methods for benefit‐risk assessment, and pharmacovigilance
Skills acquired: To adequately design studies and drug development programme appreciating the legal requirements
Developing a clinical trial protocol
Relevance: Core to any clinical study is the protocol
Duration: Half day (4 h) F2F
Topics: Role of a clinical trial protocol, regulation, elements (background, study objectives, study design, endpoints, eligibility criteria, …), and
structure of a protocol. Difference between study protocol and separate statistical analysis plan, key elements for outlining randomisation,
and statistical analysis in protocol. Case studies of good and bad protocols.
Skills acquired: To adequately describe the clinical trial and the planned analysis. Being able to write especially the statistical parts for a
clinical trial protocol.
Statistical methods for research and preclinical development
Relevance: Understanding of challenges and statistical solutions in the area of research and preclinical development
Duration: Half day (4 h) F2F
Topics: Introduction to statistics in research and preclinical development, reproducibility, complex statistical techniques in research, statistics
in preclinical safety, Dunnett and William test, Bayes approach to dose‐response characterisation, and carcinogenicity
Skills acquired: Understanding challenges in statistical consultation and evaluation of experiments in research and preclinical safety and
basic understanding of common approaches
Dose‐finding
Relevance: Dose‐finding is one of the major tasks in drug development
Duration: 2 d (16 h) F2F
Topics: Dose‐finding in drug development (overview), sequential phase I dose‐finding trials to identify an optimal dose, model‐based
Bayesian and likelihood methods for phase I trials, parallel group adaptive and nonadaptive phase II dose‐finding trials, and MCP‐Mod
methodology
Skills acquired: Understanding the dose‐finding problem inside and outside oncology. Practical design and analysis of dose‐finding trials in
phases I and II.
Advanced design
Relevance: To make efficient use of incoming and external data for decision‐making
Duration: 3 d (24 h) F2F
Topics: Randomisation and stratification, optimal designs, trial designs allowing early stopping for futility or efficacy (ie, group sequential
design), and trials that can be altered based on accumulating data (eg, sample size reassessment and treatment or subgroup selection).
Statistical methodology will include methods with pre‐fixed rules, combination tests, conditional error rates and worst‐case adjustments
and extension to more complex trial designs addressing multiple objectives (eg, closed test procedures).
Skills acquired: Optimal design, understanding of frequentist properties, and multiple testing procedures.
Pharmacological modelling
Relevance: Emphasis is on the estimation of physiologically relevant information characterising the subject dependent drug exposure and
relating it to a (un)wanted pharmacodynamical effect
Duration: 1 d (8 h) F2F
Topics: Pharmacometrics being the field closest related to biostatistics, the communalities and differences between the 2 expertises are
highlighted. Noncompartmental methods are illustrated and explained. These are extended to compartmental pharmacokinetic models and
pharmacokinetic models with differential equations. The connection with pharmacodynamics is explored, with the Emax model for
physiological effects derived from first principles, and the importance of pharmacological modelling to drug development in general is
illustrated. More broadly, the course serves as an introduction to non‐linear mixed effects modelling and its implementation in SAS
Skills acquired: Understanding of pharmacokinetics‐ and physiology‐inspired modelling.
On successful completion of the course, students should be able to fit non‐linear mixed‐effect models in SAS using proc nlmixed and interpret
the SAS output.
Advanced computational skills including efficient computing
Relevance: Efficient use of computing is vital to conduct simulation studies or implement complex statistical techniques.
Duration: Half a day (4 h) F2F/16 h online
(Continues)
JAKI ET AL. 601
TABLE 4 (Continued)
Topics: Parallel computing in R including simple approaches to making code parallelisable and the use of the parallel package in R. Dynamic
report creation via the knitr package and RMarkdown. Guided‐user interface‐based data visualisation using shiny.
Skills acquired: Ability to use multicore processors to speed up simulations. Reproducible research methods
Statistical methods for evidence synthesis
Relevance: To understand the statistical principles of systematic reviews and meta‐analysis and become able to support such reviews from the
statistical point of view
Duration: Half a day (4 h) F2F/4 h online
Topics: Overview of statistical evidence synthesis methodology, in particular, fixed‐effects and random‐effects approaches, measures of
heterogeneity, meta‐regression analysis, and brief introduction to network meta‐analysis
Skills acquired: Understanding the statistical principles for meta‐analyses and systematic reviews
Statistical inference and multiple testing:
Relevance: Enabling valid conclusions
Duration: 8 h online
Topics: Frequentist and Bayesian approaches to address specific research questions, prespecification vs exploration. Regression to the mean,
decision theory, error rates in the context of testing single and multiple hypotheses, resampling‐based methods, and closed testing.
Skills acquired: An in‐depth understanding of statistical inference to design and analyse clinical trials
Statistical learning
Relevance: Analysis of large biomedical data set
Duration: 2 d F2F/4 h online
Topics: Interdisciplinary applications of machine learning and other data science techniques, for example, in electronic health records, high
throughput screening, genomics, pharmacovigilance covering methods as regression and classification, model selection, resampling
methods, large‐scale multiple testing, and clustering.
Skills acquired: Knowledge of the concepts of statistical learning; understanding of a select set of statistical learning approaches and their
application in R.
TABLE 5 Transferable and generic skills in joint curriculum
Working in a culturally diverse environment
Relevance: To sensitise the researchers about cultural differences
Duration: 2 h F2F
Topics: Key experiences with cultural differences of assumptions, values, and ethics.
Skills acquired: An appreciation for diversity and some ideas to avoid misunderstanding.
Ethics in research
Relevance: To raise awareness about the ethical dimension of research
Duration: 4 h F2F
Topics: What ethical issues should be considered in planning and conducting research? When does the research require ethical approval?
What ethical norms are to be adhered to when publishing research results? Algorithmic responsibility.
Skills acquired: Understanding ethical considerations relevant to conducting research.
Presentation skills
Relevance: To improve presentation skills
Duration: 1 d (8 h) F2F
Topics: Planning and preparing a presentation, different presentation techniques, body language, and interacting with audience, managing
nervousness, and using voice effectively.
Skills acquired: To plan and deliver confident, effective presentations
Planning and managing a project
Relevance: To develop successful strategies for conducting a project successfully
Duration: Half a day (4 h) F2F
Topics: Planning, organising, and managing a project: Breaking projects down into “bitesized
chunks,” developing realistic timelines, and prioritisation of tasks.
(Continues)
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Skills acquired: The ability to effectively plan and organise a project and monitor the projects progress
How to make a case for funding of a research project
Relevance: Do's and don'ts when applying for research funding
Duration: Half a day (4 h) F2F
Topics: Funding application work flow, funding schemes in Europe, differences between public and industry funding, and case studies.
Skills acquired: Understanding the process to gain funding and tips for successful applications
Entrepreneurial skills for a start‐up/small company
Relevance: Enhance future career options
Duration: Half a day (4 h) F2F
Topics: (i) How to create competitive business advantages, (ii) planning and controlling (business and financial planning, risk assessment,
intellectual property right issues, …), (iii) how to reach clients (advertisement in print, social media, websites, presence at conferences, and
organisation of events), and (iv) customer acquisition (efficient presentations, contracting, price negotiations, and developing customer
loyalty).
Skills acquired: Ability to set up projects and enterprises.
Multidisciplinary collaborations
Relevance: Enabling successful collaboration in teams
Duration: Half a day (4 h) F2F
Topics: Negotiations skills, layman's presentations, eg, explaining statistical terms to a nonstatistical partner, input to nonstatistical
discussions, eg, when developing a study protocol
Skills acquired: Ability to communicate statistical concepts to nonexperts; improved communication skills.
Reproducible research
Relevance: When research fails, it can be because of mistakes made early in its development and one way to identify these mistakes is to
check if the early research findings are reproducible. Statisticians are often key collaborators in research and typically are involved in the
analysis and interpretation of data. It is therefore important that these analyses are demonstrably reproducible and statisticians will need to
learn the skills necessary to do this. This course will describe and illustrate the tools available in RStudio to help make research
reproducible.
Duration: Half a day (4 hr) F2F
Topics: Define reproducible research, highlight importance of reproducible research, and become familiar with tools (such as RMarkup) to
help make research reproducible.
Skills acquired: Ability to conduct reproducible research; knowledge of specialised tools for reproducible research.
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tical industry but also as academic researchers or within regulatory agencies. Having a harmonised European PhD cur-
riculum in place might also help to define what educational and professional knowledge is needed to be a “statistician”
in drug development.7 | DISCUSSION
While the early drug development phases are increasingly moving into the focus of applied pharmaceutical research,
this seems to be less so in the education of statistical sciences. The desire for novel statistical methodology is no longer
confined to late‐stage development, as the demand for quantitative methods to support decisions in the transition
phases surges.
The IDEAS network is a first step towards harmonising the academic education of PhD students with an interest in
early‐phase studies. It brings together all of the key skills required for a career as a research scientist in academia, the
pharmaceutical industry, CROs or regulatory agency, and for entrepreneurs embarking on statistical start‐up
companies.
The network provides access to European key opinion leaders, clinical trials experts, and other stakeholders in the
public and private sectors. The extensive course programme ensures the development of statistical expertise in design-
ing, conducting, analysing, and assessing innovative early‐phase trials. Statistical courses provide a well‐founded basis
in traditional topics relevant for early development to ensure that graduates have a broad and in‐depth competence on
state‐of‐the‐art methods. As the consortium is composed of experts in different fields, including novel methodology into
604 JAKI ET AL.the proposed curriculum and training courses is straightforward. This gives the graduates a head start, having learnt
new methods directly from their originators and early adopters in industry.
The specific courses focusing on project planning as well as the work on the individual research projects will provide
ESRS with the skills to independently develop research plans, write grant, or project proposals, which are essential for a
successful career as a research scientist in both the public and private sectors.
Dedicated training courses and regular progress presentations at the summer schools, workshops, secondments, and
research visits ensure that communication and presentation skills are acquired. Skills in scientific writing in technical,
medical journals as well as for the public will be developed. Focus is given to the ability to present complex, technical
matters to nonstatisticians such as the medical community and general public. This is to ensure a smooth translation of
methodological work from the statistical to the medical community. Transnational, cross‐sectorial secondments will
ensure that the researchers understand the needs and perspectives of different stakeholders and will enhance their mul-
ticultural competence to initiate and facilitate international research collaborations.
There is an increasing demand for biostatisticians with profound expertise in medical studies, especially in the highly
regulated field of drug development so that the graduates of IDEAS will be in high demand from a range of different
employers: They can have a career path as a scientific researcher at a university, a statistician/methodologist within
the pharmaceutical industry, or a statistician within a clinical trial unit. Similarly, regulatory and health technology
assessment bodies have an increasing demand for qualified statisticians to assess increasingly complex trial designs and
interpret the resulting data. The largest employers of biostatisticians are based on the pharmaceutical industry and CROs,
where biostatisticians are in constant high demand to work on clinical projects level as well as in methodology groups.
We believe that IDEAS is a step forward in the training of statisticians working in drug development. The IDEAS
network does, however, have 2 key shortcomings. Firstly, it is focused on early drug development, while the need for
similarly trained researchers covers the entire drug development process. Secondly, IDEAS is, at the moment, a single
initiative on a relatively small scale (14 researchers will be trained through the programme) for a limited time (from
2015 to 2018). To overcome this, our vision is to build on the principles of IDEAS to develop a joint, harmonised
PhD level programme that is cross‐sectorial, cross‐national for statisticians working in drug development. Having in
place a harmonised European PhD curriculum might also help to define what educational and professional background
constitutes a “statistician” for drug development. The key to achieving this vision is continued and even strengthened
interaction between industry and academia and a close collaboration between academic institutions across Europe
and beyond.
In our proposal, we have considered student to be full‐time although there are a number of students with in an
interest in pharmaceutical statistics that study part‐time. Many of these students work at a pharmaceutical company
or CRO alongside undertaking their PhD studies. The main challenges in accommodating such part‐time students
would be the integration of these students in the cohort of full‐time students and the requirement to take part in (inten-
sive) training weeks, which might conflict with other work commitments.FUNDING
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606 JAKI ET AL.APPENDIX A.TABLE A1 Summer school (time is given in hours [h] and days [d], whereby a full day is equivalent to 8 h)
SUMMERSCHOOL (S)
S1 (Kick‐Off) S2 S3 S4
Specialised training
Selected research presentations/lectures by renown researchers
in the field
2 h 1 h
A regulatory view of drug development 2 h
An introduction to drug development 1.5 d
Ethics in research (general, clinical trials, and regulations) 4 h
Statistical computing (parallel computing in R; shiny—interactive
data visualisation)
0.5 d
Pharmacological modelling 1 d
Practical workshop on e‐learning course “Genomics” 1 d
Adaptive methods for dose‐finding 1 d
Adaptive clinical trials 1 d
Data and safety monitoring board 0.5 d
Individually supervised research projects
Short intro to individually supervised research projects 3 h
ESR update on research projects 1 d 1 d 0.5 d
Clinical advisor experiences 1 h 1 h
Training on transferable skills
Working in a culturally diverse environment 2 h
The art of giving presentations – Soft skills training 0.5 d
Planning and managing a project 0.5 d
How to write a successful job application 0.5 d
How to successfully obtain research funding 0.5 d
How to write a business plan for a statistical consulting company 0.5 d
Developing entrepreneurial skills—how to start your own statistical company 0.5 d
Working with medical collaborators 0.5 d
Team building activities
1.5 d 1 d 0.5 d 0.5 d
All other business
Overview of project by coordinator 1 h
Partner introductions 1 h
Administrative board meeting 0.5 d 1 h 1.5 h 1.5 h
TABLE A2 E‐learning courses offered
Year Course Title
1 Computational skills in statistics
2 Genomics: technologies and data analyses
3 Multiple testing
